J&J Vaccine Is Still a Win for the Public - The Wall Street Journal

1. J&J Vaccine Is Still a Win for the Public  The Wall Street Journal
2. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial  PRNewswire
3. J&J adds to COVID-19 vaccine armoury with 66% efficacy in global trial  Reuters
4. The Johnson & Johnson Vaccine Is Only This Effective, Research Shows  Best Life
5. J&J’s Covid-19 Vaccine: How Effective Is It and When Will It Be Available?  The Wall Street Journal
6. View Full Coverage on Google News

from Top stories - Google News https://ift.tt/2Mez6qc
via